Vita Life Sciences Limited (VLS) AI Stock Analysis

Vita Life Sciences Limited, an ASX-listed life sciences company trading under the code VLS, maintains an active presence in the equity market through its ordinary fully paid shares. Its capital management decisions, particularly on-market buy-backs,...

Vita Life Sciences Limited, an ASX-listed Australian healthcare company, focuses on over-the-counter medicines, complementary and alternative therapies, dietary supplements and health foods across Australia and South East Asia. Its products are devel...

Vita Life Sciences Limited has declared an interim dividend of AUD 0.05 per ordinary fully paid share for the six-month period ended 30 June 2026, reinforcing its commitment to returning capital to investors. The dividend will trade ex on 18 Septembe...

Vita Life Sciences reported a 6.1% increase in revenue to A$48.3 million for the half year ended 30 June 2026, with profit before tax up 19.1% and net profit after tax rising 14.9% compared with the prior corresponding period. Net tangible assets per...

Vita Life Sciences Limited has updated the market on a change to its issued capital following the cancellation of 10,427 ordinary fully paid shares. The cessation of these securities occurred on 2 July 2026 as a result of an on-market share buy-back,...

Vita Life Sciences Limited has updated the market on its ongoing on-market share buy-back program, confirming that it repurchased a total of 10,424 ordinary fully paid shares prior to the most recent trading day. The latest daily notification reports...

Vita Life Sciences Limited has continued its on-market share buy-back program for its ordinary fully paid shares, as disclosed in an updated notification to the ASX dated 29 June 2026. The company reported that a total of 10,000 shares had been repur...

Vita Life Sciences Limited has converted newly issued ordinary shares under its Long Term Incentive Plan, signalling ongoing use of equity-based remuneration for employees or executives. The company issued a cleansing notice confirming that these sha...

Vita Life Sciences Limited has updated the market on a change in director Andrew O’Keefe’s interests following the issuance of 600,000 new unquoted shares under the company’s Long Term Incentive Plan. The new LTIP shares, funded via...

Vita Life Sciences Limited has notified the market of the issue of 1,005,000 unquoted performance shares under its Long Term Incentive Plan. The new securities, which are not quoted and are subject to transfer restrictions, are being issued as part o...

Vita Life Sciences has reported a change in the indirect shareholding of director Henry George Townsing following market trades conducted between 1 and 5 June 2026. Through entities associated with him, including Stanton Lea Pty Ltd as trustee for th...

Vita Life Sciences Limited, a listed life sciences company with 54,231,784 shares on issue, serves the health and wellness market through products and services in the broader pharmaceutical and nutraceutical space. Its ASX listing positions it to tap...

Vita Life Sciences Limited, listed on the ASX under ticker VLS, has ordinary fully paid shares and operates in the broader life sciences sector, though this filing does not elaborate on its precise product portfolio or regional focus. The company rem...

Vita Life Sciences Ltd has reported a change in the indirect shareholding of director Henry George Townsing following market trades conducted between 25 and 29 May 2026. Townsing disposed of 29,947 ordinary shares for total consideration of $72,226,...

Vita Life Sciences Limited reported that all resolutions put to shareholders at its 2026 Annual General Meeting were passed, reflecting solid investor support for the board’s agenda. The meeting outcomes included approval of the remuneration re...

Vita Life Sciences Limited held its 2026 Annual General Meeting on 28 May, conducted as a hybrid event with shareholders able to attend in person at its office or observe via a webinar facility managed by Automic. The meeting was declared properly co...

Vita Life Sciences Limited has completed its on-market share buy-back program of ordinary fully paid shares, initially announced in May 2025 and now formally closed with this final notification. The company repurchased 1,015,391 shares for a total co...